Pharmacokinetic modeling of carisoprodol and meprobamate disposition in adults

Carisoprodol is a widely prescribed muscle relaxant and is also a drug known to be a subject to abuse. Despite the fact that carisoprodol has been available for prescription since 1959, a number of gaps in our knowledge of the toxicokinetics of this common drug exist. For example, the volume of dist...

Full description

Saved in:
Bibliographic Details
Published in:Human & experimental toxicology 2017-08, Vol.36 (8), p.846-853
Main Author: Lewandowski, TA
Format: Article
Language:English
Subjects:
Adult
Adults
Carisoprodol - pharmacokinetics
Datasets
Death
Half-Life
Humans
Meprobamate
Meprobamate - pharmacokinetics
Metabolism
Metabolites
Models, Biological
Muscle Relaxants, Central - pharmacokinetics
Pharmacokinetics
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carisoprodol is a widely prescribed muscle relaxant and is also a drug known to be a subject to abuse. Despite the fact that carisoprodol has been available for prescription since 1959, a number of gaps in our knowledge of the toxicokinetics of this common drug exist. For example, the volume of distribution (Vd) for carisoprodol in humans has not been reported. A two-compartment pharmacokinetic model describing carisoprodol metabolism and that of the primary metabolite, meprobamate, was developed to better understand the pharmacokinetics of this drug. The model accounts for first pass metabolism of carisoprodol and was able to replicate the data from several previously reported data sets. Based on an analysis of four different data sets, the Vd for carisoprodol ranged from 0.93 to 1.3 L/kg, while that for meprobamate ranged from 1.4 to 1.6 L/kg. The model was also used to estimate the probable dose of this drug in an individual where questions concerning the drug’s role in her death had been posed. The model may, therefore, have significant utility for estimating doses of carisoprodol in medicolegal cases.
ISSN:0960-3271
1477-0903
DOI:10.1177/0960327116672912